Document:

exv10w56

 

Exhibit 10.56

CONFIDENTIAL
TREATMENT REQUESTED

MANUFACTURE AND SUPPLY AGREEMENT

     THIS MANUFACTURE AND SUPPLY AGREEMENT (the “Agreement”), dated November 13, 2006, is
between BIO-RAD LABORATORIES, INC., a Delaware corporation with offices at 1000 Alfred Nobel Drive,
Hercules, California 94547 (“BIO-RAD”) and CIPHERGEN BIOSYSTEMS, INC., a Delaware
corporation with offices at 6611 Dumbarton Circle, Fremont, California 94555 (“CIPHERGEN”).

RECITALS

     WHEREAS, BIO-RAD and CIPHERGEN have executed an Asset Purchase Agreement dated August 14, 2006
(the “APA”), pursuant to which BIO-RAD is acquiring substantially all of the assets and
certain liabilities relating to CIPHERGEN’s tools business (the “Business”);

     WHEREAS, BIO-RAD wishes to manufacture and supply PRODUCTS (as defined below) to CIPHERGEN;
and

     WHEREAS, CIPHERGEN wishes to purchase such PRODUCTS from BIO-RAD,

     NOW, THEREFORE, in consideration of the respective covenants and promises contained herein and
for other good and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the parties hereto agree as follows:

1. Definitions.

All defined terms used herein that are not defined below in this Section 1 or elsewhere
in this Agreement shall have the meanings given such terms in the APA.

	 	1.1	 	“APA” means the Asset Purchase Agreement of even date herewith between
the parties.
	 
	 	1.2	 	“Business” shall have the meaning set forth in the APA.
	 
	 	1.3	 	“Clinical Diagnostics” shall have the meaning set forth in the Cross
License Agreement of even date herewith between the parties.
	 
	 	1.4	 	“Clinical Diagnostics Market” shall have the meaning set forth in the
Cross License Agreement of even date herewith between the parties.
	 
	 	1.5	 	“Confidential Information” shall have the meaning set forth in Section
12.1 of this Agreement.
	 
	 	1.6	 	“Delivery Date” shall mean the delivery date(s) for ordered PRODUCTS.

 

 

	 	1.7	 	“Delivery Point” shall mean the delivery location(s) specified in the
applicable Purchase Order.
	 
	 	1.8	 	“Effective Date” shall mean the Closing Date (as such term is defined
in the APA).
	 
	 	1.9	 	“Manufacturing Information” shall mean the following information with
respect to the PRODUCTS: (a) instrument prototypes, if available; (b) manufacturing
drawings and specifications, including any applicable schematics; (c) manufacturing
drawings and specifications covering any special tooling and the operation thereof; (d)
manufacturing methods and procedures; (e) manufacturing records; (f) technical
know-how; (g) a detailed list of all commercially available parts, components and
software purchased or licensed on the open market, disclosing the part number, name and
location of the supplier(s) and applicable software licenses, if any; (h) with respect
to consumable items, a detailed list of all commercially available ingredients,
specifications for making ingredients that are not commercially available and tools for
producing such consumables; (i) repair specifications and test procedures for
instruments and any component parts thereof including, without limitation,
installation, operation and performance qualifications as available; (j) source code
for any software licensed for use in conjunction with instruments; (k) patent
applications and patents owned or licensed applicable to the manufacture of PRODUCTS;
(l) software licenses; and (m) quality control, testing and quality assurance
procedures.
	 
	 	1.10	 	“Purchase Orders” shall mean written orders submitted by CIPHERGEN to
BIO-RAD and containing the information set forth in Section 3.2 for the purchase of
PRODUCTS.
	 
	 	1.11	 	“QC Criteria” shall mean CIPHERGEN’s applicable incoming quality
control criteria for each PRODUCT as set forth on the attached Schedule A.
	 
	 	1.12	 	“SELDI Technology” shall mean Surface Enhanced Laser
Desorption/Ionization Technology as described in U.S. Patent Application No.
08/068,896.
	 
	 	1.13	 	“Specifications” shall mean the (a) functional specifications, (b)
technical specifications, and (c) standard operating procedures and associated
documentation, as applicable, relating to the manufacture of PRODUCTS and attached
hereto as Schedule B.
	 
	 	1.14	 	“Technology Escrow Agreement” shall mean an escrow agreement pertaining
to the Manufacturing Information that shall be established by the parties pursuant to
Section 10.3.
	 
	 	1.15	 	“PRODUCTS” shall mean those products, and any improvements or
modifications thereto acceptable to CIPHERGEN pursuant to Section 3.3, listed

2

 

	 	 	 	in Schedule C to this Agreement, as may be amended from time to time, as
well as any NEW SELDI PRODUCTS.
	 
	 	1.16	 	“NEW SELDI PRODUCTS” shall mean new products that use SELDI Technology
and are developed and sold by BIO-RAD in the ordinary course of BIO-RAD’s operation of
the Business.
	 
	 	1.17	 	“NEW CIPHERGEN PRODUCTS” shall mean new or improved products that use
SELDI Technology and are developed or manufactured by BIO-RAD at CIPHERGEN’s request
hereunder, e.g., a clinical diagnostic version of the PCS 4000 or arrays with specific
capture properties.
	 
	 	1.18	 	“Year” shall mean each twelve (12) month period ending on the
anniversary of the Effective Date of this Agreement.

2. Scope of Agreement.

	 	2.1	 	Supply of PRODUCTS. BIO-RAD agrees to manufacture and sell PRODUCTS to
CIPHERGEN as requested by CIPHERGEN. Subject to the terms and conditions of this
Agreement, BIO-RAD shall fill CIPHERGEN’s requirements for PRODUCTS, including the
manufacture, sale and delivery of PRODUCTS to CIPHERGEN, and CIPHERGEN shall purchase
from BIO-RAD CIPHERGEN’s requirements for PRODUCTS.
	 
	 	2.2	 	Technical Support and Maintenance and Repair Services. With respect to
PRODUCTS purchased by CIPHERGEN hereunder, BIO-RAD shall be responsible for providing
all applicable warranty service to CIPHERGEN pursuant to Section 6.1, and CIPHERGEN
shall be responsible for providing all technical support, warranty, maintenance and
repair services to its customers.

3. Purchase and Sale of Products.

	 	3.1	 	Forecasts. During the term of this Agreement, CIPHERGEN shall provide
quarterly, non-binding twelve (12) month rolling forecasts to BIO-RAD, which shall
include the quantity and type of PRODUCTS anticipated to be ordered and the anticipated
Delivery Date(s). CIPHERGEN may provide revised forecasts to BIO-RAD as necessary to
accommodate CIPHERGEN’s changing requirements for PRODUCTS. Forecasts shall be
provided to BIO-RAD within ten (10) business days of the end of each calendar quarter.
Failure to timely provide forecasts and revisions to forecasts may affect BIO-RAD’s
ability to meet CIPHERGEN’s requested Delivery Date(s). If CIPHERGEN places a Purchase
Order that exceeds the forecasted amount, BIO-RAD shall use reasonable efforts to fill
the Purchase Order, but shall not be liable for failing to supply any amount in excess
of the applicable forecast.

3

 

	 	3.2	 	Purchase Orders. CIPHERGEN shall initiate purchases of PRODUCTS
hereunder by submitting Purchase Orders in writing, or by facsimile or other electronic
means to BIO-RAD that reference this Agreement and include at least the following
information:

	 	(a)	 	the identity and quantity of PRODUCTS ordered;
	 
	 	(b)	 	a requested Delivery Date (subject to the applicable lead times
set forth in Section 3.7);
	 
	 	(c)	 	packing, shipping and labeling instructions;
	 
	 	(d)	 	the Delivery Point(s), including shipping address; and
	 
	 	(e)	 	a “bill to” address and contact name and telephone number.
	 
	 	3.2.1	 	Purchase Orders are subject to BIO-RAD’s acceptance, which
shall not be unreasonably withheld or delayed. BIO-RAD shall use reasonable
efforts to acknowledge Purchase Orders for PRODUCTS in writing within ten (10)
days after receipt. BIO-RAD’s acknowledgment shall note any exceptions
regarding matters such as the items ordered, configuration, pricing, shipment
date, etc., that are subject to BIO-RAD’s then current lead times. In the
event of any conflict between the terms of this Agreement and the terms of any
of CIPHERGEN or BIO-RAD’s pre-printed forms, invoices, order acknowledgements
or any other documents, the terms of this Agreement shall prevail unless
mutually agreed otherwise in a document signed by both parties. BIO-RAD shall
use reasonable commercial efforts to fulfill all Purchase Orders for the
quantities specified therein by the Delivery Date.
	 
	 	3.2.2	 	CIPHERGEN may amend any Purchase Order up to five (5) business
days after BIO-RAD’s acceptance of such Purchase Order. CIPHERGEN acknowledges
that any amendments may necessitate a change in the scheduled Delivery Date(s)
for PRODUCTS ordered under the affected Purchase Order. CIPHERGEN acknowledges
and agrees that amendments to Purchase Orders may result in changes to the
scheduled Delivery Date(s).

	 	3.3	 	Changes in Materials, Components or Suppliers. BIO-RAD shall give
CIPHERGEN as much prior written notice of any changes to materials or components used
in PRODUCTS or to any supplier of such materials or components as is commercially
practicable. CIPHERGEN shall make a good faith effort to obtain regulatory approval
for the proposed new materials or components and BIO-RAD shall not manufacture PRODUCTS
using any such modified or new materials until CIPHERGEN has obtained such regulatory
approval or granted express written consent. Notwithstanding the foregoing, CIPHERGEN
shall have the right to reject any such proposed change if any required regulatory
approval of the proposed new materials or components is not obtained and BIO-RAD shall
use reasonable commercial efforts to continue to manufacture the PRODUCTS in accordance
with the original specifications.

4

 

	 	3.4	 	Preliminary Annual Forecast. CIPHERGEN’s preliminary forecast for the
first Year of this Agreement is set forth on Schedule D. 
	 
	 	3.5	 	Minimum Purchase Commitment. For each Year of the first three Years of
this Agreement, BIO-RAD shall manufacture and deliver, and CIPHERGEN shall purchase,
accept and pay for, not less than the quantities of PRODUCTS specified on the attached
Schedule E, and for each Year thereafter for the quantities of PRODUCTS as
shall be reasonably agreed to by CIPHERGEN and BIO-RAD.
	 
	 	3.6	 	Custom Materials and Components. CIPHERGEN shall be responsible for
purchasing, and maintaining sufficient inventory levels thereof, all custom materials
and components used by BIO-RAD in the manufacture of PRODUCTS specifically for
CIPHERGEN that are not used for any other BIO-RAD products.
	 
	 	3.7	 	Lead Times. Contingent upon CIPHERGEN’s fulfillment of its forecast
obligations in Section 3.1 and subject to delays resulting from amendments to Purchase
Orders pursuant to Section 3.2.2, BIO-RAD will use commercially reasonable efforts to
deliver PRODUCT(S) on the Delivery Dates requested in CIPHERGEN’s relevant Purchase
Order or as mutually agreed upon between the parties, provided such Delivery Date
allows for a lead time of at least ninety (90) days from the date of BIO-RAD’s
acceptance of the relevant Purchase Order.

4. New Products.

	 	4.1	 	New SELDI Products. If, in the ordinary course of BIO-RAD’s operation
of the Business, BIO-RAD develops NEW SELDI PRODUCTS that BIO-RAD makes generally
available to BIO-RAD’s customer base, BIO-RAD shall make such NEW SELDI PRODUCTS
available to CIPHERGEN for purchase in accordance with Sections 3.2 and 7.1.1. If
BIO-RAD develops and sells new BIO-RAD Life Science Group products that are not NEW
SELDI PRODUCTS, BIO-RAD shall make such new products available to CIPHERGEN for
purchase at its standard list price for such products in the United States.
	 
	 	4.2	 	New Ciphergen Products. If CIPHERGEN requests that BIO-RAD develop and
manufacture NEW CIPHERGEN PRODUCTS for CIPHERGEN, or manufacture NEW CIPHERGEN PRODUCTS
to CIPHERGEN’s specifications, BIO-RAD and CIPHERGEN shall negotiate in good faith a
separate written agreement (“New Product Development and Supply Agreement”)
containing the terms pursuant to which BIO-RAD shall develop and supply such NEW
CIPHERGEN PRODUCTS to CIPHERGEN.

5

 

5. Delivery and Acceptance.

	 	5.1	 	Delivery.

	 	5.1.1	 	Packing. BIO-RAD shall pack all PRODUCTS in a manner
adequate to protect such products from loss or damage in transit and in
accordance with good commercial practice. BIO-RAD shall include in each
shipment a certificate of analysis for each lot of consumable PRODUCTS included
in any shipment.
	 
	 	5.1.2	 	Shipment. BIO-RAD shall ship PRODUCTS to CIPHERGEN
“FCA BIO-RAD’s facility” (Incoterms 2000). BIO-RAD shall prepay and invoice to
CIPHERGEN all freight, insurance, import and other shipping expenses associated
with shipments of PRODUCTS. BIO-RAD shall have the right to make partial
shipments of PRODUCTS ordered under any Purchase Order. Each shipment shall
include a packing slip containing identifying information including, without
limitation, the Purchase Order number, applicable part number(s), quantity
ordered and quantity shipped.
	 
	 	5.1.3	 	Delivery. BIO-RAD shall use commercially reasonable
efforts to deliver PRODUCTS on the Delivery Date requested by CIPHERGEN,
provided that the requested Delivery Date allows for the required lead time
specified in Section 3.7. CIPHERGEN reserves the right to refuse any delivery
received more than fifteen (15) days in advance of the scheduled Delivery Date
or any quantity of PRODUCTS in excess of the quantity specified in the relevant
Purchase Order. CIPHERGEN, at its option, may return, freight collect, all
units received more than fifteen (15) days in advance or in excess of the
quantity specified on such Purchase Order or may, at its option, retain such
units with payment therefor deferred until it otherwise would be due. BIO-RAD
shall provide prompt written notice to CIPHERGEN of any anticipated delay in
shipment.

	 	(a)	 	If BIO-RAD delivers PRODUCTS more than thirty
(30) days after the scheduled Delivery Date, and CIPHERGEN’s customer
for such PRODUCTS cancels delivery of such PRODUCT as a direct result,
CIPHERGEN shall have the right, at its sole option and without
liability, to cancel the applicable Purchase Order.

	 	5.2	 	Acceptance.

	 	5.2.1	 	PRODUCTS. CIPHERGEN shall use reasonable commercial
efforts to inspect and test delivered PRODUCTS for compliance with the
applicable QC Criteria set forth on Schedule A within seven (7)
business days after delivery. If CIPHERGEN determines that any delivered
PRODUCT does not comply with QC Criteria, CIPHERGEN shall promptly notify
BIO-RAD in writing and BIO-RAD shall use reasonable commercial efforts to
repair or replace the PRODUCT within thirty (30) days thereafter at BIO-RAD’s
expense, including but not limited to shipping charges. If CIPHERGEN does not
notify BIO-RAD of any defects within such seven (7) day period, such delivered
PRODUCTS shall be deemed accepted.

6

 

	 	 	 	Notwithstanding the foregoing, BIO-RAD and CIPHERGEN may mutually agree to
an alternate resolution for the affected PRODUCTS. CIPHERGEN’s acceptance of
PRODUCTS in accordance with this Section will not act as a waiver of
CIPHERGEN’s rights pursuant to Section 6.

6. Warranties.

	 	6.1	 	PRODUCTS. At the time of delivery BIO-RAD warrants that the PRODUCTS
shall be free from defects in materials and workmanship and shall conform to the
applicable Specifications. In addition, PRODUCTS that are instruments shall be subject
to any warranty that is provided to BIO-RAD’s other customers and PRODUCTS that are
consumables shall carry a shelf life of not less than three (3) months. If feasible,
BIO-RAD shall use commercially reasonable efforts to honor CIPHERGEN requests for a
longer shelf life. BIO-RAD’s warranty shall cover only those parts and processes
manufactured by BIO-RAD. Any alterations of or additions to the PRODUCTS made by
CIPHERGEN will not be covered.
	 
	 	6.2	 	Regulatory Compliance. BIO-RAD further warrants that PRODUCTS shall be
manufactured in accordance with the ISO 13485 Quality Management Standard for medical
devices as soon as reasonably practicable after the Effective Date.
	 
	 	6.3	 	Warranty Disclaimer. THE EXPRESS WARRANTIES STATED IN THIS AGREEMENT
ARE THE SOLE AND EXCLUSIVE WARRANTIES WITH RESPECT TO THE PRODUCTS. NO OTHER
WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, SHALL APPLY INCLUDING, BUT NOT LIMITED TO,
THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR
NONINFRINGEMENT AS WELL AS ANY WARRANTIES ARISING FROM COURSE OF DEALING, USAGE OR
TRADE PRACTICE. The stated express warranties are in lieu of all other obligations or
liabilities arising out of or in connection with this Agreement.
	 
	 	6.4	 	BIO-RAD understands and agrees that CIPHERGEN intends to resell the PRODUCTS
and the warranty provided hereunder shall not be voided due to use of such PRODUCTS by
CIPHERGEN’s customers; provided, however, that CIPHERGEN and CIPHERGEN’s agents,
employees and representatives use and store the PRODUCTS in accordance with BIO-RAD’s
reasonable written instructions, if any.

7. Prices, Invoices and Payment.

	 	7.1	 	Prices.

	 	7.1.1	 	Products. CIPHERGEN shall purchase PRODUCTS at a price
equal to [**************************************************] and (b) all

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.***

7

 

	 	 	 	applicable freight charges, insurance, taxes, duties and any other fees or
costs related to the transport, export, import or sale of PRODUCTS
(“Transport Charges”) to CIPHERGEN.
[***************************************************************************************************
****************************************************************************************************
******************************************************************************] Such prices
shall be exclusive of all applicable Transport Charges, applicable
value-added, excise, sales, use or consumption taxes, customs duties or
other governmental charges, but excluding taxes based upon or measured by or
imposed upon the income of BIO-Rad.
	 
	 	7.1.2	 	Price Adjustments. Until
[*************************************************], pricing for PRODUCTS shall
be based on
[*****************************************************************************]. Within ninety
(90) days after the Effective Date and once annually thereafter,
[***************************************] and shall promptly provide such pricing
information to CIPHERGEN.

	 	7.2	 	Invoices and Payment. BIO-RAD shall render invoices to CIPHERGEN upon
shipment of the PRODUCTS. Each invoice shall (a) be sent to the “bill to” contact or
address specified on the applicable Purchase Order, (b) include the Purchase Order
number and the aggregate and unit prices for the shipment covered by such invoice, and
(c) separately itemize any freight, insurance, duties, taxes and other costs incidental
to such shipment. CIPHERGEN shall pay each such invoice in U.S. dollars no later than
thirty (30) days after receipt.

8. Records and Audits.

	 	8.1	 	Records. Within ninety (90) days after each anniversary of the
Effective Date, BIO-RAD shall furnish to CIPHERGEN complete and accurate statements
documenting [***********************************************] the prices invoiced to
CIPHERGEN hereunder for the preceding Year. In addition, BIO-RAD shall keep and
maintain complete and accurate records of the transactions underlying the accounting
statements to be furnished including, without limitation, manufacturing records. Upon
reasonable prior notice, CIPHERGEN or its representative may inspect BIO-RAD’s records
during normal business hours to verify the accuracy of the computation of the amounts
charged pursuant to Section 7. CIPHERGEN shall not request any such audit more than
once in any twelve (12) month period. If any audit reveals that BIO-RAD has not
complied with the terms of Section 7, such that there has been an overcharge to
CIPHERGEN, then BIO-RAD shall promptly repay the amount of such overcharge to CIPHERGEN
plus interest at a rate of one and one-half percent (1.5%) if the overcharge is in
excess of five percent (5%). CIPHERGEN shall bear the cost of such audits provided
that, if any overcharge is in excess of

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.***

8

 

	 	 	 	five percent (5%) of the amount due for the period under audit, BIO-RAD shall
reimburse CIPHERGEN for CIPHERGEN’s reasonable out-of-pocket costs for the
applicable audit.
	 
	 	8.2	 	Regulatory Inspections and Audits. Upon reasonable prior notice,
BIO-RAD shall afford access to its facilities during normal business hours to the FDA
and any other state, federal or foreign regulatory agency having jurisdiction over
CIPHERGEN’s business operations in the Clinical Diagnostics Market and/or the PRODUCTS
sold by CIPHERGEN to: (a) inspect the BIO-RAD facilities where PRODUCTS are
manufactured including, without limitation, work-in-progress and finished inventory,
and (b) audit any records maintained by BIO-RAD in accordance with Section 8.1 above.
CIPHERGEN shall bear all out-of-pocket costs associated with such audits.

9. Indemnification and Limitation of Liability.

	 	9.1	 	Indemnification.

	 	9.1.1	 	Ciphergen. CIPHERGEN shall indemnify, defend or
settle and hold BIO-RAD and its affiliates, and the officers, directors,
employees and agents of each of them, harmless from and against all claims,
suits or demands, damages, losses, costs or expenses including reasonable
attorney’s fees and costs (collectively, “Claims”) arising out of or
relating to (a) the performance by CIPHERGEN of its obligations hereunder and
caused by the negligence or willful misconduct of CIPHERGEN, its employees or
agents in the performance of its obligations hereunder, or (b) any Claim that
all or any part of the specifications furnished by CIPHERGEN, and relied upon
by BIO-RAD in manufacturing the affected PRODUCTS and/or NEW CIPHERGEN
PRODUCTS, infringe upon any third-party patent, trade secret, trademark,
copyright or other proprietary right (“Third-Party IP Rights”). In the
event of any such Claim, CIPHERGEN shall have the right, at its option, in lieu
of the obligations set forth in the first sentence of this Section 9.1.1, to
procure for BIO-RAD, at no cost to BIO-RAD, the right or licenses necessary for
BIO-RAD to continue to use the allegedly infringing specifications or
modifications, or to replace or modify the allegedly infringing specifications
or modifications so that the applicable PRODUCT or NEW CIPHERGEN PRODUCT does
not infringe upon Third-Party IP Rights.
	 
	 	9.1.2	 	Bio-Rad. BIO-RAD shall indemnify, defend or settle and
hold CIPHERGEN and its affiliates, and the officers, directors, employees and
agents of each of them, harmless from and against Claims arising out of or
relating to (a) the performance by BIO-RAD of its obligations hereunder and
caused by the negligence or willful misconduct of BIO-RAD, its employees or
agents in the performance of its obligations hereunder or (b) any Claim that
any NEW SELDI PRODUCT, any NEW CIPHERGEN

9

 

	 	 	 	PRODUCT, to the extent such Claim arises out of or relates to any
specifications not provided by CIPHERGEN, or any other product purchased by
CIPHERGEN from BIO-RAD hereunder that is not a variant of or based upon to
the PRODUCTS hereunder infringes any Third-Party IP Rights. In the event of
any such infringement claim, BIO-RAD shall have the right, at its option, in
lieu of the obligations set forth in the first sentence of this Section
9.1.2, to procure for CIPHERGEN, at no cost to CIPHERGEN, the rights or
licenses necessary for CIPHERGEN to continue using the allegedly infringing
PRODUCTS or to replace or modify the allegedly infringing PRODUCTS so that
they become non-infringing.
	 
	 	9.1.3	 	Conditions. The indemnifying party’s (the
“Indemnitor”) obligations under this Section 9 are subject to the
following conditions: (a) the party to be indemnified (the
“Indemnitee”) shall give the Indemnitor prompt written notice of any
claim, (b) the Indemnitor shall have the sole authority to manage the defense
or settlement of any claim (provided that the Indemnitor shall not agree to any
settlement or compromise of any claim involving any remedy other than the
payment of monetary damages without obtaining the prior written consent of the
Indemnitee (not to be unreasonably withheld) and (c) the Indemnitee shall give
such assistance and information as the Indemnitor may reasonably require for
purposes of settling or opposing such claim. Notwithstanding the foregoing
Sections 9.1.1 and 9.1.2, the Indemnitor’s obligation to indemnify the
Indemnitee hereunder shall not extend to any Claims to the extent caused by the
Indemnitee’s negligence or willful misconduct.

10. Conditional Manufacturing Arrangements.

	 	10.1	 	Limited License. BIO-RAD acknowledges that it is CIPHERGEN’s sole
source for the supply of PRODUCTS and desires to assure CIPHERGEN of a continuing
supply of PRODUCTS for the purposes contemplated herein. Accordingly, subject to
Section 10.2, BIO-RAD hereby grants to CIPHERGEN a non-transferable, fully-paid up,
royalty-free, worldwide, non-exclusive license, to make, use, sell, offer for sale
and/or import the PRODUCTS in the field of Clinical Diagnostics into the Clinical
Diagnostics Market, or to have any of these done on its behalf, in accordance with this
Section 10. The license rights granted to CIPHERGEN herein are expressly subject to,
and CIPHERGEN shall only be entitled to exercise such rights if, and for such period of
time as:

	 	(a)	 	BIO-RAD or its successor in interest (collectively referred to
in this Section 10 as “BIO-RAD”) fails to manufacture for or sell
PRODUCTS to CIPHERGEN as the result of the occurrence of any of the conditions
set forth below, and BIO-RAD fails to cure such condition within forty-five
(45) days after its receipt of written notice thereof from CIPHERGEN:

10

 

	 	i.	 	BIO-RAD is liquidated or dissolved and is
unable or unwilling to fulfill BIO-RAD’s obligations hereunder;
or
	 
	 	ii.	 	BIO-RAD (i) files a voluntary petition under
bankruptcy or insolvency law, (ii) makes an assignment of substantially
all of its business assets for the benefit of its creditors, or (iii)
an involuntary petition in bankruptcy or insolvency is filed against
BIO-RAD or a receiver or trustee is appointed for substantially all of
BIO-RAD’s business assets; or
	 
	 	iii.	 	BIO-RAD ceases business operations; or
	 
	 	iv.	 	BIO-RAD ceases or otherwise discontinues
the manufacture and/or supply of PRODUCTS; or
	 
	 	v.	 	BIO-RAD is in material breach of any
material provision of this Agreement in a manner related to BIO-RAD’s
supply obligations hereunder and fails to cure such breach within a
thirty (30) day period (or such additional period of time as mutually
agreed is reasonably required to cure such material breach so long as
the cure is commenced within such thirty (30) day period and thereafter
diligently pursued to completion, provided that BIO-RAD shall apply no
less effort to cure such breach than it would exert on behalf of any of
its other customers); or
	 
	 	vi.	 	BIO-RAD terminates this Agreement for
convenience; or

	 	(b)	 	BIO-RAD fails to sell any NEW SELDI PRODUCTS to CIPHERGEN as
requested by CIPHERGEN in accordance with the terms and conditions of this
Agreement within forty-five (45) days after BIO-RAD’s receipt of CIPHERGEN’s
written request to purchase such NEW SELDI PRODUCT(S); or
	 
	 	(c)	 	BIO-RAD fails to manufacture for or sell NEW CIPHERGEN PRODUCTS
to CIPHERGEN as requested by CIPHERGEN in accordance with the terms and
conditions of this Agreement and the New Product Development and Supply
Agreement within one hundred eighty (180) days of BIO-RAD’s receipt of
CIPHERGEN’s written request for such NEW CIPHERGEN PRODUCTS and all applicable
and necessary product specifications and other information necessary for the
manufacture of such NEW CIPHERGEN PRODUCT(S), or such additional period of time
as shall be reasonably necessary for BIO-RAD to manufacture such NEW CIPHERGEN
PRODUCT(S) provided that BIO-RAD is using reasonable commercial efforts to do
so;
	 
	 	(d)	 	Following the expiration of the term of this Agreement.

	 	10.2	 	Use of Manufacturing Information. Provided this Agreement has not been
terminated by CIPHERGEN for its convenience, in the event of the occurrence of any of
the conditions described in Section 10.1 above, subject to Section 11.3, CIPHERGEN
shall have the limited right to receive and use the applicable

11

 

	 	 	 	Manufacturing Information for purposes of manufacturing or having manufactured the
specific PRODUCTS or NEW CIPHERGEN PRODUCTS affected by such condition for the
purposes contemplated herein for so long as such condition remains uncured.
CIPHERGEN shall pay a reasonable royalty to BIO-RAD on sales of any such PRODUCTS or
NEW CIPHERGEN PRODUCTS manufactured by or for CIPHERGEN for sale to CIPHERGEN’s
customers.
	 
	 	10.3	 	Escrow Agreement. Within sixty (60) days after the execution of this
Agreement, the parties shall establish an escrow with a mutually acceptable escrow
agent (the “Escrow Agent”) pursuant to a mutually acceptable form of Technology
Escrow Agreement. BIO-RAD shall deposit the Manufacturing Information, and any updates
thereof, into such escrow pursuant to the terms of the Technology Escrow Agreement.
Subject to the terms of the Technology Escrow Agreement, in the event of the occurrence
of any of the conditions specified in Section 10.1, CIPHERGEN shall have the right to
require the Escrow Agent to deliver to CIPHERGEN the applicable Manufacturing
Information deposited by BIO-RAD into escrow. CIPHERGEN shall bear responsibility for
paying all expenses associated with such escrow.
	 
	 	10.4	 	Ownership of Manufacturing Information. Nothing in this Agreement
shall be construed to grant any right of ownership in the Manufacturing Information to
CIPHERGEN or grant any other right or interest not expressly provided.

11. Term and Termination.

	 	11.1	 	Term. Unless terminated (a) by either party in accordance with
Section 11.2, or (b) by either party for convenience upon one hundred eighty (180)
days’ prior written notice to the other party, this Agreement shall be effective for a
period of five (5) years commencing on the Effective Date (the “Initial Term”).
At the option of CIPHERGEN, the Agreement may be renewed for two (2) successive two
(2) year periods (each a “Renewal Term”) upon not less than ninety (90) day’s
notice prior to the expiration of the then-current Term.
	 
	 	11.2	 	Termination for Default. Either party may terminate this Agreement upon
notice to the other party if the other party is in material default of any provision of
this Agreement and fails to cure such default within thirty (30) days after notice
thereof by the non-defaulting party (or such additional period of time as mutually
agreed by the parties is reasonably required to cure such material breach so long as
the cure is commenced within such thirty (30) day period and thereafter diligently
pursued to completion).
	 
	 	11.3	 	Effect of Termination. Provided this Agreement was not terminated due
to CIPHERGEN’s material default and failure to cure, CIPHERGEN shall have the right to
continue to use or sell any PRODUCTS in its possession on the effective date of the
termination or expiration of this Agreement, in accordance with the terms and
conditions of this Agreement. If CIPHERGEN terminates this

12

 

	 	 	 	Agreement for BIO-RAD’s material default, CIPHERGEN shall have the right to use the
Manufacturing Information for purposes of manufacturing and selling PRODUCTS in
accordance with Section 10. Together with any provisions which by their nature are
intended to survive, the provisions of Sections 2.2, 6.1, 6.3, 6.4, 7.2, 8, 9, 10,
11.3, 12, 13.3 and 13.9 shall survive any termination of this Agreement.

12. Confidentiality, Publicity.

	 	12.1	 	CIPHERGEN and BIO-RAD acknowledge that by reason of their relationship to each
other hereunder, each will have access to certain information and materials concerning
the other’s business, plans, customers and product(s) (including but not limited to
information and materials contained in technical data provided from time to time) which
is confidential and of substantial value to the owner (the “Confidential
Information”), which value would be impaired if such information were disclosed to
third parties. Each party (the “receiving party”) expressly agrees not to disclose,
directly or indirectly, the Confidential Information disclosed by the other party
(“disclosing party”) to any third party, unless the express prior written consent of
the disclosing party has been obtained. The receiving party expressly agrees not to
use the disclosing party’s Confidential Information except as expressly authorized by
the disclosing party, or as necessary to perform its obligations under this Agreement.
In this regard, the receiving party agrees to maintain the Confidential Information in
confidence and shall take at least the same precautions to avoid disclosure of such
Confidential Information as those it would take with its own Confidential Information,
but in no case less than reasonable precautions. It is also agreed between the parties
that all Confidential Information shall remain the sole and exclusive property of the
disclosing party. Upon termination or expiration of this Agreement for any reason, the
receiving party shall promptly return to the disclosing party all documents embodying
the Confidential Information of the disclosing party, except that one copy may be
retained for archival purposes.
	 
	 	12.2	 	Neither party shall not make any press releases or other publicity regarding
this Agreement or any part thereof without prior written consent of the other party.

13. Miscellaneous Provisions.

	 	13.1	 	Assignment. Neither this Agreement nor any of the rights or
obligations hereunder may be assigned by either party without the prior written consent
of the other party, except that either party may, without such consent, assign all such
rights and obligations to a wholly-owned subsidiary or partnership of which the
assigning party is the general partner, or any assignee or purchaser of the portion of
such party’s business associated with the rights and obligations hereunder. In the
event of any such transfer, the transferee shall assume and be bound by the provisions
of this Agreement. Subject to the foregoing, this Agreement shall be binding upon and
inure to the benefit of the parties hereto and their respective

13

 

	 	 	 	successors and permitted assigns, and no other person shall have any right, benefit
or obligation under this Agreement as a third-party beneficiary or otherwise.
	 
	 	13.2	 	Notices. All notices, requests, demands and other communications
which are required or may be given under this Agreement shall be in writing and shall
be deemed to have been duly given when received if personally delivered; when
transmitted if transmitted by facsimile; the day after it is sent, if sent for next day
delivery to a domestic address by recognized overnight delivery service (e.g., Federal
Express); and upon receipt, if sent by certified or registered mail, return receipt
requested. In each case, notice shall be sent to:

If to BIO-RAD :

Bio-Rad Laboratories, Inc.

1000 Alfred Nobel Drive

Hercules, California 94547

Attention: General Counsel

Facsimile No.: 510.741.5815

with a copy to:

Bio-Rad Laboratories, Inc.

2000 Alfred Nobel Drive

Hercules, California 94547

Attention: Vice President, Life Science Group

Facsimile No.: (510) 741-5803

If to CIPHERGEN

Ciphergen Biosystems, Inc.

6611 Dumbarton Circle

Fremont, California 94555

Attention: Vice President of Operations

Facsimile No.: 510.505.2101

	 	 	 	or to such other place and with such other copies as either party may designate as to itself by written notice to the other party.
	 
	 	13.3	 	Choice of Law/Dispute Resolution. 

	 	(a)	 	Choice of Law. This Agreement shall be construed,
interpreted and the rights of the parties determined in accordance with the
laws of the State of California (without reference to the choice of law
provisions), except with respect to matters of law concerning the internal
corporate affairs of any corporate entity which is a party to or the subject of
this Agreement.

14

 

	 	(b)	 	Dispute Resolution. The parties shall attempt to
resolve informally, through their respective representatives on the Joint
Steering Committee (as such term is defined in the APA), any dispute, claim or
controversy (“Dispute”) arising between the parties with respect to the
performance of this Agreement or any PRODUCTS manufactured for and sold to
CIPHERGEN hereunder. If such representatives are unable to resolve any such
Dispute within 60 days, the party raising the Dispute shall promptly advise the
other party in a writing (“Notice of Dispute”) of its desire to submit
the Dispute to an alternative dispute resolution (“ADR) process. The
Notice of Dispute shall describe the nature of the Dispute in reasonable
detail. By not later than 10 business days after the recipient has received
such Notice of Dispute, each party shall have selected for itself a
representative who shall have the authority to bind each such party and shall
additionally have advised the other party in writing of the name and title of
such representative. By not later than 20 business days after the date of such
Notice of Dispute, such representatives shall schedule a date for engaging in
an ADR process. Thereafter, the representatives of the parties shall engage in
good faith in an ADR process. If the representatives of the parties have not
been able to resolve the Dispute within 30 business days after the termination
of the ADR, the parties shall have the right to pursue any other remedies
legally available to resolve such dispute in either the State Courts of
California or in the United States District Courts for California. Each party
irrevocably and unconditionally (1) agrees that any ADR process, suit, action
or other legal proceeding arising out of this Agreement may be brought in the
United States District Court for the Northern District of California or, if
such court does not have jurisdiction or will not accept jurisdiction, in any
court of general jurisdiction in Contra Costa County, California, (2) consents
to the jurisdiction or any such court in any such suit, action or proceeding
and (3) waives any objection which such party may have to the laying of venue
of any such suit, action or proceeding in any such court. Notwithstanding the
foregoing, nothing in this Section 10.4(b) shall be construed to waive any
rights or timely performance of any obligations existing under this Agreement.

	 	13.4	 	Entire Agreement; Amendments and Waivers. This Agreement, together
with all exhibits hereto, and the Confidentiality Agreement constitutes the entire
agreement between the parties pertaining to the subject matter hereof and supersedes
all prior agreements, understandings, negotiations and discussions, whether oral or
written, of the parties.  This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the parties hereto. No amendment, supplement,
modification or waiver of this Agreement shall be binding unless executed in writing by
the party to be bound thereby.  No waiver of any of the provisions of this Agreement
shall be deemed or shall constitute a waiver of any other provision hereof (whether or
not similar), nor shall such waiver constitute a continuing waiver unless otherwise
expressly provided.

15

 

	 	13.5	 	Multiple Counterparts.  This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.
	 
	 	13.6	 	Invalidity.  In the event that any one or more of the provisions
contained in this Agreement or in any other instrument referred to herein, shall, for
any reason, be held to be invalid, illegal or unenforceable in any respect, then to the
maximum extent permitted by law, such invalidity, illegality or unenforceability shall
not affect any other provision of this Agreement or any other such instrument.
	 
	 	13.7	 	Attorneys’ Fees. If any party to this Agreement brings an action to
enforce its rights under this Agreement, the prevailing party shall be entitled to
recover its costs and expenses, including without limitation reasonable attorneys’
fees, incurred in connection with such action, including any appeal of such action.
	 
	 	13.8	 	Independent Contractors. CIPHERGEN and BIO-RAD, and their respective
agents, shall be independent contractors with respect to the transactions contemplated
herein and nothing herein shall be deemed to constitute a relationship of partnership,
joint venture, employee-employer or any other relationship other than that of
independent contracting parties. Neither party, nor its agents shall hold itself out to
third parties as having the power to contractually bind the other party with respect to
any matter.
	 
	 	13.9	 	Limitation of Liability. IN NO EVENT SHALL EITHER PARTY, ITS
SUBSIDIARIES OR AFFILIATES BE LIABLE TO THE OTHER PARTY, ITS SUBSIDIARIES OR
AFFILIATES, FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR
LOST PROFITS, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE)
ARISING IN ANY WAY OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES.
	 
	 	13.10	 	Force Majeure. Neither party shall be responsible for any delay or
failure in performance (or for any loss, damage, cost, charge or expense incurred or
suffered by the other party by reason of such delay or failure) if that delay or
failure is a result of an event beyond the reasonable control of that party, and
without the fault or negligence of that party.
	 
	 	13.11	 	Quest Diagnostics. The parties expressly acknowledge that Quest
Diagnostics Incorporated (“Quest Diagnostics”) is an intended third-party
beneficiary of this Agreement with respect to Ciphergen’s supply and support
obligations for PRODUCTS as set forth in the Strategic Alliance Agreement dated July
22, 2005 (the “SAA”) between Ciphergen and Quest Diagnostics and the applicable
agreement(s) between Ciphergen and Quest Diagnostics for the supply of PRODUCTS. To
the extent CIPHERGEN is obligated to supply PRODUCTS to

16

 

	 	 	 	Quest Diagnostics pursuant to the SAA and subject to the terms and conditions of
this Agreement, BIO-RAD agrees to provide such PRODUCTS to CIPHERGEN in fullfillment
of such obligations.
	 
	 	13.12	 	Construction. Section headings are used for convenience only and
shall in no way affect the construction of this Agreement. Whenever a number of days
is specified in this Agreement, the number of days shall be construed as calendar days,
unless business days are specified.

[Signatures on Following Page]

17

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their authorized
representatives.

	 	 	 	 	 	 	 	 	 	 	 
	BIO-RAD LABORATORIES, INC.	 	 	 	CIPHERGEN BIOSYSTEMS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By: 

Name:

	 	/s/ Norman Schwartz
 

Norman Schwartz
	 	 
	 	By:

Name:
	 	/s/ Debra Young
 

Debra Young
	 	 
	Its:

	 	President
	 	 	 	Its:
	 	Chief Financial Officer and	 	 
	 

	 	 	 	 	 	 	 	Vice President of Finance	 	 

18

 

The following Schedules are attached hereto and incorporated herein by this reference. Where the
Agreement and Schedules conflict, the Agreement shall prevail.

	 	 	 	 	 
	 

	 	Schedule A:
	 	Quality Control Criteria
	 
	 	 	 	 
	 

	 	Schedule B:
	 	Specifications
	 
	 	 	 	 
	 

	 	Schedule C:
	 	Products
	 
	 	 	 	 
	 

	 	Schedule D:
	 	Preliminary Annual Forecast
	 
	 	 	 	 
	 

	 	Schedule E:
	 	Minimum Purchase Commitment

19

 

Schedule A

CIPHERGEN’s Quality Control Criteria

See attached.

20

 

Schedule A, QC Criteria

[*********]

	 	 	 
	[**********************]
	 	[**********]

CHIPWARE

	 	 	 
	PRODUCT	 	QCP
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]
	[**********************]
	 	[**********]

KITWARE

	 	 	 	 	 
	PRODUCT	 	QCP
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	[**********************]
	 	[**********]
	
	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	[**********************]

	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	 

	 	[**********************]
	 	[**********]
	[**********************]

	 		 	[**********]
	[**********************]

	 	 	 	[**********]
	[**********************]

	 	 	 	[**********]

	***	 	Confidential
treatment requested pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.***

 

Document Register

	 	 	 
	Document Type	 	Status
	[**********************************]

	 	[******************]

[****************]

	 	 	 	 	 	 	 	 	 
	Number	 	Document Title	 	Rev. No.	 	Active Date	 	Change Number
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	 

	 	 	 	Approved By	 	 	 	 

			
	 	 	 
	[***************************]
	 	[*************]
	 
	 	[********]

	***	 	Confidential
treatment requested pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.***

Page 1 of 2

 

	 	 	 	 	 	 	 	 	 
	Number	 	Document Title	 	Rev. No.	 	Active Date	 	Change Number
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	[*********]

	 	[*****************************]
	 	[*****]
	 	[*********]	 	 
	 

	 	 	 	Approved By	 	 	 	 

			
	 	 	 
	[***************************]
	 	[*************]
	 
	 	[********]

	***	 	Confidential
treatment requested pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.***

Page 2 of 2

 

Schedule B

Specifications

See attached.

21

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]

	***	 	Confidential
treatment requested pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.***

Page 1 of 1

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]
	[**********]

	 	[**************************************]
	 	[****]
	 	[***********]

	***	 	Confidential
treatment requested pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.***

Page 1 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 2 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 3 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 4 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 5 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 6 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 7 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 8 of 9

 

Manufacturer and Supply Agreement

Schedule B — [*********************]

	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]
	[**********]
	 	[**************************************]

	 	[****]
	 	[***********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

Page 9 of 9

 

Schedule C

Products

See attached.

22

 

Catalog Items

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	[*	************]	 	 	 	 
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	[*	************]	 	 	 	 
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	[*	************]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

 

 

Catalog Items

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	***********]	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*************]	 	 	 	 	 	 	 	 
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*******]	 	 	 	 	 	 	 	 
	 
	 	 	[*	******]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

 

 

Catalog Items

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**************]	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*******]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	*************]	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

 

 

Catalog Items

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	*********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	***********]	 	 	 	 

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

 

 

Catalog Items

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	 	 	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*************]	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	 	 	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	*************]	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	 	 	 	 	 	 
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**********]	 	 	 	 
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**********]	 	 	 	 
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	************]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	[*	**********]	 	 	[*	**************]	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	**************]	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[*	***********]	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

 

 

Catalog Items

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	**********]	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***********]
	 	 	[*	*************]	 	 	[*	********]	 	 	[*	*********]	 	 	[*	*************]	 	 	[*	**************]	 	 	[*	********]
	 
	 	 	[*	*************]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	[*	********]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

 

 

Schedule D

Preliminary Annual Forecast

Instruments
=     [********]

ProteinChip®
Arrays =     [*********] *

 

			
	*	 	Where one (1) ProteinChip® Array equals an eight-spot strip.

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

23

 

Schedule E

Minimum Purchase Commitment

	 	 	 	 	 	 	 	 	 	 	 
	PRODUCTS	 	Year 1	 	Year 2	 	Year 3	 	Year 4	 	Year 5
	Instruments

	 	[******]
	 	[******]
	 	[******]
	 	[******]
	 	[******]
	 
	 	 
	 	 
	 	 
	 	 
	 	 
	ProteinChip® Arrays
	 	[*******]
	 	[*******]
	 	[*******]
	 	[*******]
	 	[*******]
	 
	 	 
	 	 
	 	 
	 	 
	 	 

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

24exv10w58

 

Exhibit 10.58

CONFIDENTIAL
TREATMENT REQUESTED

CROSS LICENSE AGREEMENT

     THIS CROSS LICENSE AGREEMENT (the “Agreement”), dated November 13, 2006 (the
“Effective Date”), is between BIO-RAD LABORATORIES, INC., a Delaware corporation with offices at
1000 Alfred Nobel Drive, Hercules, California 94547 (“BIO-RAD”) and CIPHERGEN BIOSYSTEMS,
INC., a Delaware corporation with offices at 6611 Dumbarton Circle, Fremont, California 94555
(“CIPHERGEN”).

RECITALS

     WHEREAS, BIO-RAD and CIPHERGEN have entered into an Asset Purchase Agreement of even date
herewith (the “APA”), pursuant to which BIO-RAD is acquiring certain assets and liabilities
of CIPHERGEN related to the Business (as such term is defined below);

     WHEREAS, BIO-RAD is licensing back to CIPHERGEN rights for limited commercial exploitation of
the Proprietary Rights acquired by BIO-RAD from CIPHERGEN pursuant to the APA; and

     WHEREAS, CIPHERGEN is licensing to BIO-RAD rights under CIPHERGEN Intellectual Property (as
such term is defined below),

     NOW, THEREFORE, in consideration of the respective covenants and promises contained herein and
for other good and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the parties hereto agree as follows:

	1.	 	Definitions.
	 
	 	 	All defined terms used herein that are not defined below in this Section 1 or elsewhere in
this Agreement shall have the meanings given such terms in the APA.

	 	1.1	 	“APA” shall mean the Asset Purchase Agreement of even date herewith
between the parties.
	 
	 	1.2	 	“Business” shall have the meaning given such term in the APA.
	 
	 	1.3	 	“CIPHERGEN Exclusivity Period” shall mean a period of five (5) years
after the Effective Date.
	 
	 	1.4	 	“Clinical Diagnostics” shall mean, in the clinical medical practice,
the assaying, testing or determination of, inside or outside of a living human or
animal, one or more biomarkers in or on any test sample for the purpose of identifying,
characterizing, defining or diagnosing a disease state (including, without limitation,
determining the state of health of a human or animal) to identify, treat or prevent
disease, as well as the screening, prognosis, therapeutic monitoring and/or evaluation
of the progression of any disease. For the avoidance of doubt, if an assay is being
performed on a living animal, or on animal tissue or other sample derived from a living
animal, for the

 

 

	 	 	 	purpose of Food Testing, such application shall not be considered a Clinical
Diagnostic.
	 
	 	1.5	 	“Clinical Diagnostics Developer” shall mean any Laboratory within any
entity (including CIPHERGEN) engaged in the research and development and/or manufacture
or sale of product, processes or services for Clinical Diagnostics purposes.
	 
	 	1.6	 	“Clinical Diagnostics Market” shall mean (1) Clinical Diagnostics
Developers, (2) Commercial Clinical Laboratories, (3) Collaborators, (4) home-users of
Clinical Diagnostic assays, and (5) physician’s office user of Clinical Diagnostic
assays.
	 
	 	1.7	 	“Collaborator” shall mean any Laboratory within any entity with whom
CIPHERGEN has agreed to collaborate, in writing and with prior written notification to
BIO-RAD, in research and development activities related to products, processes or
services for Clinical Diagnostic purposes. During the CIPHERGEN Exclusivity Period, the
number of such Collaborators shall not increase by more than [****] per year nor total
more than [****], including collaborators existing as of the Effective Date.
Collaborators existing as of the Effective Date are identified on Schedule A attached
hereto.
	 
	 	1.8	 	“Commercial Clinical Laboratory” shall mean any clinical Laboratory
(including, without limitation, laboratories contained within a hospital, physician’s
office or other similar treatment center, e.g., urgent care centers, chronic care
facilities and stand-alone Laboratories that collect samples for purposes of testing)
engaged in the sale of products, processes or services for Clinical Diagnostic
purposes.
	 
	 	1.9	 	“Confidential Information” shall have the meaning set forth in the
Confidentiality Agreement dated August 14, 2006 between the parties.
	 
	 	1.10	 	“Food Testing” shall mean the analysis of food, including a living
animal committed to the human or animal food chain, for the purpose of quality
assurance or quality control of such food, or for the purpose of identifying,
characterizing, defining or diagnosing a disease state solely for the purpose of
determining the safety or suitability for consumption of such food.
	 
	 	1.11	 	“Intellectual Property” shall mean patent applications, patents,
methods, processes, technical information, know-how, copyrights, trade secrets and
trademarks.
	 
	 	1.12	 	“Improvements” shall mean any Intellectual Property invented by BIO-RAD
or CIPHERGEN after the Effective Date that is useful for SELDI as described in U.S.
Pat. App. No. 08/068,896 and patents and applications claiming priority thereto,
including, for example, capturing analytes onto a solid support for presentation to a
laser source for laser desorption/ionization analysis.
	 
	 	 	 	***
Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.***

-2-

 

	 	1.13	 	“Joint Steering Committee” shall have the meaning given such term in
the APA.
	 
	 	1.14	 	“Laboratory” shall mean any laboratory equipped for scientific research
and/or engaged in the development, manufacture and/or sale of products, processes or
services including, without limitation, clinical reference laboratories.
	 
	 	1.15	 	“Proprietary Rights” shall have the meaning given such term in the
APA.

	2.	 	License Grants.

	 	2.1	 	License Grant to CIPHERGEN. BIO-RAD hereby grants CIPHERGEN a fully
paid-up, irrevocable, royalty free, worldwide, license and/or sublicense, including the
right to sublicense in the field of Clinical Diagnostics only, under the Proprietary
Rights to make, have made, use, sell, offer for sale, import and otherwise commercially
exploit any products, processes and services (a) in the field of Clinical Diagnostics
into the Clinical Diagnostics Market, and (b) for internal research, development, and
commercialization by CIPHERGEN and its Collaborators related to products, processes,
and services in the field of Clinical Diagnostics into the Clinical Diagnostics Market,
and including CIPHERGEN’s internal activities related to discovering biomarkers,
developing diagnostic tests, and in its capacity as a Clinical Diagnostics Developer or
Commercial Clinical Laboratory. This license shall be exclusive to CIPHERGEN, even as
to BIO-RAD subject only to the restrictions set forth in Sections 5.1 and 5.2, during
the CIPHERGEN Exclusivity Period. Upon the expiration of the CIPHERGEN Exclusivity
Period, such license shall remain exclusive, but not as to BIO-RAD, but who shall have
no right to sublicense the Proprietary Rights in the field of Clinical Diagnostics,
except as may be required by its customers or end users.
	 
	 	2.2	 	License Grant to BIO-RAD. CIPHERGEN hereby grants BIO-RAD a fully
paid-up, irrevocable, royalty-free, worldwide, non-exclusive license, under all retained
CIPHERGEN Intellectual Property (not otherwise licensed or assigned to BIO-RAD under this
Agreement or under the APA) existing as of the Effective Date to make, have made, use,
sell, offer for sale, import and otherwise commercially exploit the products, processes
and services of the Business (as such term is defined in the APA) for sale outside of the
field of Clinical Diagnostics.
	 
	 	2.3	 	Reservation of Rights. Each party reserves any rights not expressly granted
to the other party under the terms of this Agreement or any related agreement.

	3.	 	Ownership and Control of Intellectual Property.

	 	3.1	 	Improvements. All Improvements created after the Effective Date (a)
solely by BIO-RAD, shall be owned solely by BIO-RAD, (b) solely by CIPHERGEN, shall be
owned solely by CIPHERGEN and (c) jointly by the parties, shall be jointly owned
(“Joint IP”). All such joint development efforts shall be deemed to be joint
research for purposes of the CREATE Act, 35 USC §103(c)2.

-3-

 

	 	3.2	 	Prosecution of Joint Patents. The Joint Steering Committee shall
determine, with respect to any particular Joint IP, whether and how to prepare and
prosecute patent applications directed to the Joint IP (“Joint Patent Rights”).
Unless otherwise decided by the Joint Steering Committee, the parties shall share
equally in the costs of preparing and prosecuting such patent applications. However,
if one party decides not to share in these costs, then it shall assign its rights in
such patent application(s) to the other party for a reasonable price to be negotiated.
The assignee shall then have the right to take over full control of preparing and
prosecuting the patent applications and maintaining any patents.
	 
	 	3.3	 	Enforcement of Joint Patent Rights. All litigation or other
similar proceedings related to the Joint Patent Rights shall be directed and controlled
by the parties jointly, and, except as set forth herein, neither party shall have the
right to commence, direct or control any such litigation or proceedings (“Claims”)
without the express prior written consent of the other party. Each party shall (a)
select and retain counsel reasonably acceptable to the other party, (b) provide
reasonable prior notice to the other party of any settlement offer that relates to the
Joint Patent Rights in question, and obtain from such other party its prior written
consent to any such settlement to the extent that it relates to Joint Patent Rights,
which consent shall not be unreasonably withheld and (c) not fail or otherwise cease to
defend such claims without first giving the other party reasonable notice and an
opportunity to assume the control and defense of such Claims. In the case where the
parties jointly direct and control the prosecution or defense of Claims, each party
shall bear 50% of the associated costs and expenses (“Costs”). If a non-named
party elects not to participate in the direction and control of the defense of Claims
pursuant to this Section 3.3, then such party shall not have any obligation to bear any
of the Costs and shall not be entitled to any share of damages. Any recovery in
connection with a Claim involving Joint Patent Rights shall first be first applied
towards the reimbursement of the participating party or parties’ Costs (including
without limitation attorneys’ fees, expert witness fees, court costs and other
litigation costs and expenses). Any remainder after such reimbursement is made in
accordance with the foregoing shall be equally divided between the parties.

	4.	 	Right to Negotiate a License.

	 	4.1	 	BIO-RAD hereby grants CIPHERGEN the first right to engage in good-faith
negotiations with BIO-RAD to obtain a non-exclusive, worldwide license (under
commercially reasonable terms) under any Improvements created or developed by BIO-RAD
after the Effective Date and during the CIPHERGEN Exclusivity Period, owned by
BIO-RAD, for the commercialization of products, processes and services in the Clinical
Diagnostics Field.
	 
	 	4.2	 	CIPHERGEN hereby grants BIO-RAD the first right to engage in good-faith
negotiations with CIPHERGEN to obtain a non-exclusive license under commercially
reasonable terms under any Improvements created or developed by CIPHERGEN after the
Effective Date and during the CIPHERGEN Exclusivity Period and owned

-4-

 

	 	 	 	by CIPHERGEN, for the commercialization of products, processes and services outside
the Clinical Diagnostics Field.

	5.	 	Field of Use. BIO-RAD hereby acknowledges that it is CIPHERGEN’s intent to focus its business
activities on the commercialization of products, processes and services in the field of
Clinical Diagnostics into the Clinical Diagnostics Market after the Effective Date.
Accordingly, BIO-RAD expressly agrees as follows:

	 	5.1	 	BIO-RAD shall not sell products or services in the field of Clinical
Diagnostics into the Clinical Diagnostics Market that utilize the Proprietary Rights,
nor enter into a collaboration, license, or other agreement with any third party to
sell any such products or services, for a period of 5 years after the Effective Date.
	 
	 	5.2	 	Subject to Section 5.1 above, BIO-RAD shall not sell products or services in
the field of Clinical Diagnostics into the Clinical Diagnostics Market that utilize any
mass spectrometry technology, nor enter into a collaboration, license, or other
agreement with any third party to sell any such products or services, for a period of
[**********] after the Effective Date.
	 
	 	5.3	 	During the CIPHERGEN Exclusivity Period, BIO-RAD shall affix a notice to each
instrument sold by BIO-RAD which incorporates or utilizes the Proprietary Rights, or
include a notice in a users manual or other marketing or sale literature accompanying
such products, said notice stating that no rights of use are granted in the field of
Clinical Diagnostics. Bio-Rad will notify its customers who buy SELDI technology
products that they should contact Bio-Rad if they wish to assign their exclusive
diagnostic rights to any intellectual property developed by them using such products.
When Bio-Rad is contacted by any such customer wishing to assign such rights, Bio-Rad
shall promptly notify Ciphergen with the name and contact information of such customer
so that Ciphergen may contact such customer directly to seek such assignment of rights.

	6.	 	Representations and Warranties.

	 	6.1	 	Representations and Warranties. Each party represents and warrants to the
other that: (a) it has the full right, power and authority to enter into this Agreement
and fully perform its obligations under this Agreement and (b) has the right to grant the
licenses granted under this Agreement and (c) its performance of its obligations under
this Agreement is not prohibited by or in conflict with any agreement between that party
and any third party.
	 
	 	6.2	 	Warranties from APA. The warranties set forth in the APA continue to apply
and are not limited by the terms of this Agreement.
	 
	 	6.3	 	Disclaimer. WITHOUT LIMITING SECTIONS 6.1 AND 6.2, EXCEPT AS EXPRESSLY SET
FORTH IN THIS AGREEMENT OR THE APA: (a) THE PROPRIETARY RIGHTS LICENSED BY BIO-RAD TO
CIPHERGEN
	 
	 	 	 	***Confidential
treatment requested pursuant to a request for confidential treatment filed with
the Securities and Exchange Commission. Omitted portions have been filed
separately with the Commission.***

-5-

 

	 	 	 	HEREUNDER AND THE INTELLECTUAL PROPERTY LICENSED BY CIPHERGEN TO BIO-RAD HEREUNDER
ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND AND (b) CIPHERGEN AND BIO-RAD
EACH MAKES NO, AND HEREBY DISCLAIMS, ALL OTHER WARRANTIES, WHETHER EXPRESS,
STATUTORY OR IMPLIED INCLUDING, WITHOUT LIMITATION, ALL WARRANTIES OF
NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

	7.	 	TERM AND TERMINATION

	 	7.1.	 	Term. Unless terminated earlier pursuant to this Section 7, the term of this
Agreement shall commence on the Effective Date and continue in full force and effect until
expiration, revocation or invalidation of the last patent included in the Proprietary
Rights or the abandonment of the last patent application within the Proprietary Rights,
whichever is later.
	 
	 	7.2.	 	Termination for Breach. In the event of a material breach of this Agreement,
the nonbreaching party shall be entitled to terminate this Agreement by written notice to
the breaching party, if such breach is not cured within ninety (90) days after written
notice is given by the nonbreaching party to the breaching party specifying the breach.
However, if the party alleged to be in breach of this Agreement disputes such breach within
such ninety (90) day period, the nonbreaching party shall not have the right to terminate
this Agreement unless it has been determined by a court of competent jurisdiction that this
Agreement was materially breached, and the breaching party fails to comply with its
obligations hereunder within ninety (90) days after such determination.
	 
	 	7.3.	 	Survival.

	 	7.3.1.	 	Termination of this Agreement for any reason shall not release either party hereto
from any liability which at the time of such termination has already accrued to the
other party.
	 
	 	7.3.2.	 	Sections 1, 6, 7, 9, and Sections 10.1, 10.4 and 10.5 shall survive the expiration
and any termination of this Agreement. Except as otherwise provided in this Section 7,
all rights and obligations of the parties under this Agreement shall terminate upon the
expiration or termination of this Agreement.

	8.	 	INFRINGEMENT BY THIRD PARTY

	 	8.1.	 	Enforcement. During the term of this Agreement, in the event that either party
hereto reasonably believes that any Proprietary Rights are being infringed or otherwise
misappropriated by a third party or in the event that a declaratory judgment action is
brought against such party with respect to any Proprietary Rights, such party shall
promptly notify the other party.

-6-

 

	 	8.2.	 	Market Based Enforcement. As between the parties to this Agreement, CIPHERGEN
(itself or through others) shall, at its expense, have the initial right (during the
CIPHERGEN Exclusivity Period) to control the enforcement of the Proprietary Rights (each
for the purposes of this Section 8, an “Enforcement Action”) in the field of Clinical
Diagnostics, and BIO-RAD shall have the right to control any Enforcement Action outside the
field of Clinical Diagnostics.
	 
	 	8.3.	 	Failure to Enforce. In the event that either Party does not initiate an
Enforcement Action to enforce the Proprietary Rights against commercially significant
infringement or misappropriation by a third party in a country, within one hundred eighty
(180) days of a request by the other Party to initiate such Enforcement Action or
thereafter diligently pursue such Enforcement Action, the requesting Party or its designee
may initiate an Enforcement Action against such infringement or misappropriation at its own
expense. Notwithstanding the foregoing, CIPHERGEN shall have the exclusive right to
sublicense any alleged infringer in the Field of Clinical Diagnostics pursuant to Section 2
above, and BIO-RAD shall have the exclusive right to sublicense any alleged infringer
outside of the Field of Clinical Diagnostics.
	 
	 	8.4.	 	Cooperation. The non-controlling party shall, at the controlling Party’s
reasonable request and expense, fully cooperate with the party controlling any Enforcement
Action, including but not limited to, using commercially reasonable efforts to cause its
employees testify at such an action and to make available relevant records, papers and
information. The party controlling the Enforcement Action shall keep the non-controlling
party reasonably informed of the progress of such action, and the non-controlling shall
have the right to participate in such Enforcement Action with counsel of its own choice at
its own expense.
	 
	 	8.5.	 	Division of Recoveries. All recoveries from an Enforcement Action shall be
first applied to reimburse the controlling party and then the non-controlling party’s
unreimbursed expenses, including without limitation, reasonable attorneys’ fees and court
costs. Any remainder shall be divided between the parties as follows:

	 	8.5.1.	 	To the extent the amount recovered reflects lost profits in the Field of Clinical
Diagnostics, CIPHERGEN shall retain the remainder; or
	 
	 	8.5.2.	 	To the extent the amount recovered reflects lost profits outside of the Field of
Clinical Diagnostics to BIO-RAD.
	 
	 	8.5.3.	 	To the extent the amount recovered reflects lost profits both in the Field of
Clinical Diagnostics and outside the Field of Clinical Diagnostics, the remainder shall
be divided between the parties based on the percentage of lost profits attributed to
such Field.

-7-

 

	9.	 	PATENT PROSECUTION

	 	9.1.	 	Prosecution by BIO-RAD. Subject to Section 9.2 below, BIO-RAD shall have the
right, at its option, to control the filing for, prosecution and maintenance of the patents
under the Proprietary Rights, provided however that BIO-RAD shall first notify CIPHERGEN as
to the filing, prosecution and maintenance of such patents and patent applications and
shall furnish to CIPHERGEN copies of non-internal, non-privileged documents relevant to any
such filing, prosecution and maintenance, and shall consider the comments of CIPHERGEN and
its counsel in good faith. For purposes of this Section 9, “prosecution and maintenance”
of patents and patent applications shall be deemed to include, without limitation, the
conduct of interferences or oppositions, and/or requests for re-examinations, reissues or
extensions of patent terms. BIO-RAD shall pay all fees and legal expenses for the filing
for, prosecution and maintenance of the Proprietary Rights. If BIO-RAD elects to abandon
or no longer pay the expenses of a patent or patent application within the Proprietary
Rights in any country, BIO-RAD shall notify CIPHERGEN not less than thirty (30) days prior
to such action so that CIPHERGEN may decide whether to assume ownership and financial
responsibility of such patent or patent application.
	 
	 	9.2.	 	Prosecution by CIPHERGEN. Notwithstanding anything contained herein to the
contrary, CIPHERGEN, shall be entitled to control the prosecution and maintenance of U.S.
Patent 6,734,022 (the “SELDI Patent”), until the date of the final determination of the
re-examination status of the SELDI Patent, and thereafter BIO-RAD shall control such
prosecution and maintenance as provided in Section 9.1. CIPHERGEN agrees to use its best
efforts to gain reissue of U.S. Patent 6,734,022 and maintain all SELDI patent rights.

	10.	 	GENERAL

	 	10.1.	 	Governing Law. This Agreement shall be governed by, and construed and
interpreted in accordance with, the laws of California, without regard to conflicts of laws
principles.
	 
	 	10.2.	 	Independent Contractors. The relationship of CIPHERGEN and BIO-RAD
established by this Agreement is that of independent contractors. Nothing in this
Agreement shall be construed to create any other relationship between CIPHERGEN and
BIO-RAD. Neither party shall have any right, power or authority to assume, create or incur
any expense, liability or obligation, express or implied, on behalf of the other.
	 
	 	10.3.	 	Assignment. This Agreement may not be assigned by either Party without the
prior written consent of the other party, except to a party that succeeds to all or
substantially all of business or assets relating to this Agreement whether by sale, merger,
operation of law or otherwise; provided that such assignee or transferee agrees in writing
to be bound by the terms and conditions of this Agreement, and further provided that the
assignor or transferor provides prompt notice of such assignment to the non-assigning
Party.

-8-

 

	 	10.4.	 	Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR
ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING
LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM
RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING
NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF
THE POSSIBILITY OR LIKELIHOOD OF SAME.
	 
	 	10.5.	 	Notices. Any notice or other communication required by this Agreement shall
be made in writing and given by prepaid, first class, certified mail, return receipt
requested or by overnight courier or fax, and shall be deemed to have been served on the
date received by the addressee at the following address or such other address as may from
time to time be designated to the other party in writing:

	 	 	 	 	 
	 

	 	If to BIO-RAD:
	 	BIO-RAD LABORATORIES, INC
	 

	 	 	 	1000 Alfred Nobel Drive
	 

	 	 	 	Hercules, CA 94547
	 

	 	 	 	Attn: Sanford S. Wadler
	 

	 	 	 	       General Counsel
	 
	 	 	 	 
	 

	 	If to CIPHERGEN:
	 	CIPHERGEN
	 

	 	 	 	Ciphergen Biosystems, Inc.
	 

	 	 	 	Attn: Vice President for Intellectual Property
	 

	 	 	 	6611 Dumbarton Circle
	 

	 	 	 	Fremont, CA 94555
	 

	 	 	 	(510) 505-2100 (tel.)
	 

	 	 	 	(510) 505-2101 (fax)
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Wilson Sonsini Goodrich & Rosati
	 

	 	 	 	650 Page Mill Road
	 

	 	 	 	Palo Alto, California 94304-1050
	 

	 	 	 	Attn: Michael J. O’Donnell

	 	10.6.	 	Compliance with Law. Both parties shall comply with all applicable federal,
state and local laws and regulations in connection with its activities pursuant to this
Agreement.
	 
	 	10.7.	 	Modification; Waiver. This Agreement may not be altered, amended or modified
in any way except by a writing signed by both parties. The failure of a party to enforce
any provision of this Agreement shall not be construed to be a waiver of the right of such
party to thereafter enforce that provision or any other provision or right.
	 
	 	10.8.	 	Headings. Headings included herein are for convenience only, do not form a
part of this Agreement and shall not be used in any way to construe or interpret this
Agreement.

-9-

 

	 	10.9.	 	Severability. If any provision of this Agreement shall be found by a court to
be void, invalid or unenforceable, the same shall be reformed to comply with applicable law
or stricken if not so conformable, so as not to affect the validity or enforceability of
the remainder of this Agreement.
	 
	 	10.10.	 	Entire Agreement. The parties hereto acknowledge that this Agreement and its
Exhibits set forth the entire agreement and understanding of the parties hereto as to the
subject matter hereof, and supersedes all prior discussions, agreements and writings in
respect hereto.
	 
	 	10.11.	 	Counterparts. This Agreement may be executed in counterparts, each of which
shall be deemed an original, but both of which together shall constitute one and the same
instrument.

[SIGNATURES ON FOLLOWING PAGE]

-10-

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their authorized
representatives.

	 	 	 	 	 	 	 	 	 	 	 
	BIO-RAD LABORATORIES, INC.	 	 	 	CIPHERGEN BIOSYSTEMS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Norman Schwartz
 

	 	 	 	By:
	 	/s/ Debra Young
 

	 	 
	Name:

	 	Norman Schwartz
	 	 	 	Name:
	 	Debra Young	 	 
	Its:

	 	President
	 	 	 	Its:
	 	Chief Financial Officer and	 	 
	 

	 	 	 	 	 	 	 	Vice President of Finance	 	 

-11-

 

Schedule A

LIST OF CURRENT COLLABORATORS

	 	 	 
	Institution	 	Principal Investigator* 
	 
	 	 
	The Johns Hopkins University

	 	Dr. Daniel Chan
	 
	 	 
	McGill University

	 	Drs. Brian Ward and Momar Ndao
	 
	 	 
	Rigshospitalet, Copenhagen University Hospital

	 	Dr. Claus Hǿgdall and the Pelvic Mass Group
	 
	 	 
	Goteborg University

	 	Dr. Kaj Blennow
	 
	 	 
	Sahlgrenska Academy at Goteborg University

	 	Drs. Karin Sundfeldt, Björg Kristiansdottir, and Mats Brannstrom
	 
	 	 
	University College London

	 	Dr. Ian Jacobs
	 
	 	 
	The University of Kentucky

	 	Dr. Paul DePriest
	 
	 	 
	The University of Texas M.D. Anderson Cancer
Center

	 	Drs. Robert Bast, Stanley Hamilton and
Li Mao, Lajos Pusztai, Massimo Cristofanilli
	 
	 	 
	The University of Texas Medical Branch

	 	Drs. David Gorenstein, John Petersen and Ned Snyder
	 
	 	 
	The Colorado Center for Reproductive Medicine

	 	Dr. Mandy Katz-Jaffe
	 
	 	 
	Katholieke Universiteit Leuven

	 	Prof. Dr. Ignace Vergote
	 
	 	 
	The Ohio State University Research Foundation/
	 	 
	The Ohio State University

	 	Dr. Haifeng Wu
	 
	 	 
	Stanford University

	 	Dr. John Cooke

 

			
	*	 	The term “Principal Investigator” includes the members of each Principal Investigator’s
professional staff, graduate students, undergraduate students and employees of the applicable
institution engaged in collaborative research with Ciphergen.

-12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]